Ambit Biosciences Corp
AMBI
AMBI was delisted on the 10th of November, 2014.
46 hedge funds and large institutions have $78.8M invested in Ambit Biosciences Corp in 2014 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 4 closing their positions.
275% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 4
56% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 9
31% more funds holding
Funds holding: 35 → 46 (+11)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less capital invested
Capital invested by funds: $79.3M → $78.8M (-$508K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.47M |
| 2 |
CA
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
|
+$753K |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$651K |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$605K |
| 5 |
IG
ING Group
Amsterdam,
Netherlands
|
+$531K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$1.89M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$908K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$627K |
| 4 |
HCM
Highbridge Capital Management
New York
|
-$268K |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$142K |
AMBI Hedge Fund Activity: Q1 2014 in Review
46 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Ambit Biosciences Corp (AMBI) for Q1 2014, worth a combined $78.8M — down 0.64% from $79.3M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new AMBI positions and 4 closed out — a net gain of 11 holders — while 14 added to existing stakes and 9 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.47M. The largest seller was Redmile Group, cutting an estimated $1.89M.
- 46 institutional investors held Ambit Biosciences Corp (AMBI) as of Q1 2014, up from 35 in Q4 2013.
- Funds reported $78.8M of Ambit Biosciences Corp stock for Q1 2014, down 0.64% quarter-over-quarter.
- 15 funds opened new Ambit Biosciences Corp positions in Q1 2014 and 4 closed out, a net change of +11 holders.
- The largest Ambit Biosciences Corp buyer in Q1 2014 was Vanguard Group, an estimated $1.47M added.
- The largest Ambit Biosciences Corp seller in Q1 2014 was Redmile Group, an estimated $1.89M sold.
Based on aggregated 13F filings for Q1 2014.